2022 / 03

DOI: 10.24075/brsmu.2022.036

ORIGINAL RESEARCH

A new strategy in selection of hormone therapy for endometrial proliferative process in postmenopausal patients

Savelieva GM, Breusenko VG, Kareva EN, Golukhov GN, Gutorova DS, Ovchinnikova AV, Ivanovskaya TN, Shcherbatyuk KV
About authors

Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Dina S. Gutorova
Lobachevskogo, 42, Moscow, 119415, Russia; ur.relbmar@d-avorotug

About paper

Funding: the study was carried out as a part of "Molecular pharmacological markers of recurrence for proliferative processes of the reproductive tract tissues in postmenopausal patients" 2018–2020 research project at the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (universal decimal classifier 577.21; R&D No. АААА-А18-118051590095-4; info reg. ID No. АААА-Б20-220100690049-5)

Author contribution: Savelieva GM — design and supervision; Breusenko VG — clinical supervision; Kareva EN — laboratory supervision, laboratory tests and analysis of the data; Golukhov GN — consulting, data interpretation, manuscript editing; Gutorova DS — concept, patient database construction, statistical processing, analysis and interpretation of the data, manuscript writing; Ovchinnikova AV — statistical processing of the data; Ivanovskaya TN — formal analysis; Shcherbatyuk KV — patient data management.

Compliance with ethical standards: the study was approved by Ethical Review Board at the Pirogov Russian National Research Medical University (Protocol № 210 of 30 August 2021). All patients provided voluntary informed consent for the study.

Received: 2022-05-18 Accepted: 2022-06-13 Published online: 2022-06-28
|
  1. Kaprin AD, Starinskij VV, Shaxzadova AO, redaktory. Sostoyanie onkologicheskoi pomoshhi naseleniyu Rossii v 2020 godu. M.: ̆ MNIOI im. P.A. Gercena, 2021; 239 s. Russian.
  2. Kurcer MA, Breusenko VG, Goluxov GN, Golova YuA, Esipova IA, Ovchinnikova AV, et al. Diagnostika i lechenie dobrokachestvennyx vnutrimatochnyx zabolevaniĭ u pacientok v postmenopauze. Voprosy ginekologii, akusherstva i perinatologii. 2019; 18 (3): 71–79. Russian.
  3. Vetter MH, Smith B, Benedict J, Hade EM, Bixel K, Copeland LJ, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol. 2020; 222 (1).
  4. Dumanovskaya MR, Chernuxa GE, Tabeeva GI, Asaturova AV. Giperplaziya ehndometriya: poisk optimal'nyx reshenii i strategiĭ . ̆ Akusherstvo i ginekologiya. 2021; 4: 23–31. Russian.
  5. Mittermeier T. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Mittermeier T, Farrant C, Wise MR. Cochrane Database Syst Rev. 2020; 9 (9): CD012658. DOI: 10.1002/14651858.CD012658.pub2.
  6. Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. Clin Exp Obstet Gynecol. 2013; 40: 122–6.
  7. Ashrafyan LA, Antonova IB, Ivashina SV, Babaeva NA, Aleshikova AI, Baranov II. Optimizaciya diagnosticheskoi ̆ taktiki u pacientok s anomal'nymi matochnymi krovotecheniami v periody peri- i postmenopauzy. Akusherstvo i ginekologiya: Novosti. Mneniya. Obucheniya, 2019; 1 (23). Dostupno po ssylke (data obrashheniya: 07.06.2021): https://cyberleninka.ru/ article/n/optimizatsiya-diagnosticheskoy-taktiki-u-patsientok-s- anomalnymi-matochnymi-krovotecheniya-v-periody-peri-ipostmenopauzy. Russian.
  8. Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020; 126 (12): 2775–83. DOI: 10.1002/cncr.32822.
  9. Unanyan AL, Sidorova IS, Kogan EA, Baburin DV. Klinikopatogeneticheskie osobennosti giperplasticheskix processov ehndometriya u zhenshhin perimenopauzal'nogo vozrasta. RMZh «Medicinskoe obozrenie». 2018; 1 (I): 67–71. Russian.
  10. Patel MV, Shen Z, Rodriguez-Garcia M, Usherwood EJ, Tafe LJ, Wira CR. Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women. Front Immunol. 2021. Available from: https://DOI.org/10.3389/fimmu.2021.657326.
  11. Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X. Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer. J Cancer. 2020; 11 (7): 1693–701. DOI: 10.7150/jca.41943.
  12. Kadagidze Z. G. Subpopulyacii limfocitov pri zlokachestvennom roste. Vopr. onkologii. 1984; 1: 90–97.
  13. Dama A, Baggio C, Boscaro C, Albiero M, Cignarella A. Estrogen Receptor Functions and Pathways at the Vascular Immune Interface. Int J Mol Sci. 2021; 22 (8): 4254. Available from: https:// doi.org/10.3390/ ijms22084254.
  14. Bouman A, Schipper M, Heineman MJ, Faas M. 17beta-estradiol and progesterone do not influence the production of cytokines from lipopolysaccharide-stimulated monocytes in humans. Fertil Steril. 2004; 82 (Suppl 3): 1212–9.
  15. Fisenko VP, redaktor. Rukovodstvo po ehksperimental'nomu (doklinicheskomu) izucheniyu novyx farmakologicheskix veshhestv. M.: Remedium, 2000; 398 s. Russian.
  16. Saveleva GM, Breusenko VG, Kareva EN, i dr. Izuchenie roli ehkspressii genov receptorov ehstrogenov i progesterona v vozniknovenii proliferativnyx processov v ehndometrii dlya resheniya voprosa o taktike vedeniya bol'nyx s ukazannymi patologicheskimi izmeneniyami ehndometriya. Rossijskij vestnik akushera-ginekologa. 2018; 18 (6): 17–24. DOI: 10.17116/ rosakush20181806117. Russian.
  17. Savelyeva GM, Breusenko VG, Kareva EN, Ivanovskaya TN, Tikhonov DA, Gutorova DS. Steroid-receptor profile of the peripheral blood mononuclear cells in postmenopausal patients with endometrial proliferative processes. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2019;18 (3): 80–86. DOI: 10.20953/1726-1678-2019-3-80-86. Russian.
  18. Obata T, Nakamura M, Mizumoto Y, Iizuka T, Ono M, Terakawa J, et al. Dual expression of immunoreactive estrogen receptor — and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS ONE; 12 (11): 2017: e0188641. Available from: https://doi. org/10.1371/journal.pone.0188641.
  19. Singh P, Chaurasia A, Dhingra V, Misra V. Expression of ERα and PR in Various Morphological Patterns of Abnormal Uterine Bleeding-Endometrial causes in Reproductive Age Group. J Clin Diagn Res. 2016;10 (8): EC06-EC9. DOI: 10.7860/ JCDR/2016/19565.829.
  20. Swasti. Estrogen and progesterone receptors in endometrial cancer: where are we today? Gynecol Obstet. 2018; 8: 2. DOI: 10.4172/2161-0932.1000e127.
  21. Greca A, Bellora N, Dily F, Jara R, Nacht AS, Oliete JQ, et al. Chromatin topology defines estradiol-primed progesterone receptor and PAX2 binding in endometrial cancer cells. 2022; eLife. 11: e66034. Available from: https://doi.org/10.7554/ eLife.66034.
  22. Sinreih M, Knific T, Thomas P, Frković Grazio S, Rižner TL. Membrane progesterone receptors — and — have potential as prognostic biomarkers of endometrial cancer. J Steroid Biochem Mol Biol. 2018; 178: 303–11. DOI: 10.1016/j.jsbmb.2018.01.011. PMID: 29353001.
  23. Trenti A, Tedesco S, Boscaro C, Trevisi L, Bolego C, Cignarella A. Estrogen, Angiogenesis, Immunity and Cell Metabolism: Solving the Puzzle. Int J Mol Sci. 2018; 19 (3): 859. DOI: 10.3390/ ijms19030859. PMID: 29543707. PMCID: PMC5877720.
  24. Navarro FC. Herrnreiter C, Nowak L, Watkins SK. Estrogen Regulation of T-Cell Function and Its Impact on the Tumor Microenvironment. Gender and the Genome. 2018; 2 (3): 81–91. DOI: 10.1177/2470289718801379 journals.sagepub.com/home/gng.
  25. Arruvito L, et al. NK Cells Expressing a Progesterone Receptor Are Susceptible to Progesterone-Induced Apoptosis. J Immunol. 2008; 180 (8): 5746–5753. DOI: https://doi.org/10.4049/ jimmunol.180.8.5746.
  26. Polikarpova AV, Levina IS, Sigai NV, Zavarzin IV, Morozov IA, Rubtsov PM, Guseva AA, Smirnova OV, Shchelkunova TA. Immunomodulatory effects of progesterone and selective ligands of membrane progesterone receptors. Steroids. 2019; 145: 5–18. DOI: 10.1016/j.steroids.2019.02.009. Epub 2019 Feb 10. PMID: 30753845.
  27. Hasni MS, Yakimchuk K. Expression and effects of ligand-activated estrogen receptors in chronic lymphocytic leukemia. Anticancer research. 2019; 39: 167–172. DOI: 10.21873/anticanres.13093.
  28. Shen Q, Zou S, Sheng B, Zhao M, Sun LZ, Zhu X. Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas. Drug Des Devel Ther. 2019; 13: 3161–70. DOI: 10.2147/DDDT. S212157. PMID: 31564832. PMCID: PMC6731989.
  29. Lukovic J, Milosavljević Z, Zečević Luković T, Mitrović M, Andjelković M, et al. Antitumor effect of mifepristone on human endometrial stromal cell line. Vojnosanitetski Pregled. 2021; 78 (6).
  30. Kırıcı P, Tanrıverdi E. Effects of different progesterone doses on the concentrations of proinflammatory and anti-inflammatory cytokines in pregnant women with threatened abortion. 2021; 13 (11): e19333. DOI: 10.7759/cureus.19333.